Photo: NDTV Profit
Business & Finance
Sun Pharma Brokerage Review: Citi, HSBC Maintain Buy; BofA Retains Underperform
TL;DR
- Ilumya's US sales challenges, higher R&D spending, and the growth prospects of Leqselvi and Unloxcyt remain key factors shaping brokerage views on Sun Pharma.
Short summary
Our full write-up is on its way. For the complete story, read the original report:
Nov 2, 2026 · Updated 11/2/2026, 6:43:08 AM · Reported with: NDTV Profit
Sources (1)
NRI Bytes writes its own articles from the reporting below.
NDTV Profit — Sun Pharma Brokerage Review: Citi, HSBC Maintain Buy; BofA Retains UnderperformUp next · Business & Finance
Bitcoin rattled by biggest crypto heist in history! Why Warren Buffett and Charlie Munger hated cryptocurrency
Read next →
More stories
Business & Finance
Big tech share buybacks plunge 83% as AI spending hits cash flows
45m ago
Business & Finance
Explained: Why gold investors should tone down expectations as yellow metal plunges to a 1-year low
45m ago
Business & Finance
Nasdaq Outlook: Is the worst over for AI-fuelled tech stocks?
45m ago
Business & Finance
OECD PISA 2025 rankings: Check where the US, China, India, UK, and Russia stand
1h ago
